| Theme | New evolution of vitamin D | |
|---|---|---|
| Title | Vitamin D analogs for secondary hyperparathyroidism treatment | |
| Publish Date | 2012/07 | |
| Author | Masahide Mizobuchi | Department of Nephrology, Showa University School of Medicine |
| Author | Taihei Suzuki | Department of Nephrology, Showa University School of Medicine |
| Author | Tadao Akizawa | Department of Nephrology, Showa University School of Medicine |
| [ Summary ] | The classical pathogenesis of secondary hyperparathyroidism is a decrease in serum calcium levels due to hyperphosphatemia and reduced active vitamin D. As secondary hyperparathyroidism progresses, the expression of parathyroid calcium-sensing and vitamin D receptors decrease. Recently, fibroblast growth factor-23 has been shown to play roles in the pathogenesis of secondary hyperparathyroidism. Calcitriol (active vitamin D3), which activates parathyroid vitamin D receptors and suppresses parathyroid hormone, has been restricted to its clinical application for secondary hyperparathyroidism because of calcemic action. Therefore, vitamin D analogs which are less calcemic and phosphatemic are becoming standards of treatment for secondary hyperparathyroidism. Currently, maxacalcitol, falecalcitriol, paricalcitol, and doxercalciferol are applied in clinical settings. | |